This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall
by Zacks Equity Research
Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag
by Zacks Equity Research
Seagen (SGEN) and Astellas Pharma announce that the FDA has accepted the label expansion-seeking application for the Padcev/Keytruda combo under priority review to treat first-line bladder cancer.
Pfizer's (PFE) New Products May Drive Long-Term Sales Growth
by Kinjel Shah
Though Pfizer's (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is expected to drive long-term sales and profit growth.
Seattle Genetics (SGEN) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Seattle Genetics (SGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump
by Zacks Equity Research
Pfizer (PFE) reports mixed third-quarter 2023 results. It re-affirms its 2023 sales and earnings guidance provided earlier this month.
Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to Decline
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer's (PFE) Ulcerative Colitis Pill Etrasimod Gets FDA Nod
by Zacks Equity Research
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
Nurix (NRIX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.
Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
by Zacks Equity Research
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study
by Zacks Equity Research
Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.
Company News for Sep 25, 2023
by Zacks Equity Research
Companies In The News Are: F, ATVI, MSFT, SGEN, SCHL.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nurix (NRIX) Stock Increases 9% in a Month: Here's Why
by Zacks Equity Research
The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medicines for cancer.
Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals
by Zacks Equity Research
Seagen (SGEN) and Genmab announce that the late-stage study of Tivdak in the second-line treatment of adult patients with recurrent or metastatic cervical cancer meets the primary and secondary goals.
Why Is Seattle Genetics (SGEN) Up 6.5% Since Last Earnings Report?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
by Zacks Equity Research
Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.
Pfizer's (PFE) New Multiple Myeloma Drug Elrexfio Gets FDA Nod
by Zacks Equity Research
The FDA's accelerated approval of Pfizer's (PFE) new multiple myeloma drug Elrexfio/elranatamab is based on data from the pivotal phase II MagnetisMM-3 study.
Pfizer (PFE) Seems Well-Poised for Long-Term Growth: Here's How
by Zacks Equity Research
Though Pfizer's (PFE) revenues from COVID products are declining sharply, it is set to launch some key non-COVID products in 2023, which can drive long-term sales and profit growth.
Seattle Genetics (SGEN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Seattle Genetics (SGEN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -44.87% and 8.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?